• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.

Biocartis CSO Geert Maertens gives an overview of the progress and future prospects of the company.

Many biotech management teams fail to reach out to investors in a clear and appealing way.

Five entirely synthetic yeast chromosomes were created this year. By 2018 every chromosome is expected to have a synthetic couterpart, resulting in en entirely synthetic genome.

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.

Biocartis CSO Geert Maertens gives an overview of the progress and future prospects of the company.

Many biotech management teams fail to reach out to investors in a clear and appealing way.

Five entirely synthetic yeast chromosomes were created this year. By 2018 every chromosome is expected to have a synthetic couterpart, resulting in en entirely synthetic genome.

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.